Khalid El Bairi (editor) - Ovarian Cancer Biomarkers: Mapping to Improve Outcomes
Here you can read online Khalid El Bairi (editor) - Ovarian Cancer Biomarkers: Mapping to Improve Outcomes full text of the book (entire story) in english for free. Download pdf and epub, get meaning, cover and reviews about this ebook. year: 2021, publisher: Springer, genre: Home and family. Description of the work, (preface) as well as reviews are available. Best literature library LitArk.com created for fans of good reading and offers a wide selection of genres:
Romance novel
Science fiction
Adventure
Detective
Science
History
Home and family
Prose
Art
Politics
Computer
Non-fiction
Religion
Business
Children
Humor
Choose a favorite category and find really read worthwhile books. Enjoy immersion in the world of imagination, feel the emotions of the characters or learn something new for yourself, make an fascinating discovery.
- Book:Ovarian Cancer Biomarkers: Mapping to Improve Outcomes
- Author:
- Publisher:Springer
- Genre:
- Year:2021
- Rating:3 / 5
- Favourites:Add to favourites
- Your mark:
Ovarian Cancer Biomarkers: Mapping to Improve Outcomes: summary, description and annotation
We offer to read an annotation, description, summary or preface (depends on what the author of the book "Ovarian Cancer Biomarkers: Mapping to Improve Outcomes" wrote himself). If you haven't found the necessary information about the book — write in the comments, we will try to find it.
Khalid El Bairi (editor): author's other books
Who wrote Ovarian Cancer Biomarkers: Mapping to Improve Outcomes? Find out the surname, the name of the author of the book and a list of all author's works by series.
Ovarian Cancer Biomarkers: Mapping to Improve Outcomes — read online for free the complete book (whole text) full work
Below is the text of the book, divided by pages. System saving the place of the last page read, allows you to conveniently read the book "Ovarian Cancer Biomarkers: Mapping to Improve Outcomes" online for free, without having to search again every time where you left off. Put a bookmark, and you can go to the page where you finished reading at any time.
Font size:
Interval:
Bookmark:
This Springer imprint is published by the registered company Springer Nature Singapore Pte Ltd.
The registered company address is: 152 Beach Road, #21-01/04 Gateway East, Singapore 189721, Singapore
To my parents (Mohammed and Fatima) and my family for always supporting me
To my friends young oncologists and researchers on ovarian cancer worldwide
And, particularly to cancer patients
Ovarian cancer is often referred to as a silent killer. In the Western world, it is the most lethal gynecological disease, and the fifth most common cancer-related death in women. One reason for the high mortality is a lack of specific symptoms in postmenopausal women and accurate diagnostic testing for detection of the disease at early stages as well as the inevitable development of treatment resistance. Although the 5-year death rate has slightly decreased in the last decade, the overall prognosis and quality of life has not improved substantially. That said, there are major advances being made in ovarian cancer research that have improved the understanding of the disease and might ultimately lead to the development of new therapeutic options. Since the discovery of ovarian cancer, a long road of research has been explored. Ovarian carcinoma is actually no longer considered to be one disease but a spectrum of pathologies with subtype-specific molecular and clinical features. In this book edited by my friend Khalid El Bairi from Morocco, Chap. presents how recent innovative technologies applied to the development of precision medicine, guided by tumor phenotype, can be optimized for the identification of actionable molecular targets. Recent advances in the field continue to push the boundaries of our understanding of this disease and help the evolution of treatments to manage ovarian cancer so that it is no longer the silent killer we know today. I hope that this book will be valuable in offering up-to-date knowledge on this topic for a broad range of ovarian cancer specialists worldwide.
We wrote this book with love for oncology and cancer research
Khalid El Bairi
This book is a part of the annual scientific activities of the Cancer Biomarkers Working Group and OVANORDEST studies.
Funding: No funding was received for writing this book.
is the principal investigator of OVANORDEST studies and the founder of The Cancer Biomarkers Working Group, and he is currently pursuing clinical and translational research in medical oncology. He has published many peer-reviewed articles in the field of predictive and prognostic cancer biomarkers to improve survival outcomes in several WoS and Medline-indexed journals. His research focuses particularly on biomarkers for digestive and gynecological cancers such as ovarian and colorectal malignancies. He is currently a member of the board of various international scientific societies such as the International Gynecologic Cancer Society (IGCS), European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), European Society of Gynaecological Oncology (ESGO), and the American Association for Cancer Research (AACR). He is also an editor and reviewer for more than 40 academic journals and a guest editor for several special issues on emerging topics in gynecological cancers such as platinum-resistant ovarian cancer. He is also highly interested in teaching evidence-based medicine, clinical research methods, and publishing ethics to medical and PhD students and was selected for the 70th Lindau Nobel Laureate Meeting as a young scientist.
Since the emergence of data about the natural history of ovarian cancer (OC) approximately 150 years ago, tremendous advances have been made in the area of the molecular pathology of this aggressive cancer. However, OC remains one of the most lethal gynecological cancers worldwide, with no adequate screening and prevention program available yet to avoid diagnosis in advanced stages. Despite OC still being the silent killer, it has seen dynamic shifts in its classification, staging, and theories regarding its origins in the last years. In fact, the term OC has experienced a shift to include primary peritoneal and tubal cancer, as these tumors behave identically. The prognosis and treatment of OC are dependent on multiple factors, including tumor biology and extent of tumor spread, which has recently been reclassified in a new FIGO staging system. In the literature throughout the years, attempts to identify the origins of these heterogeneous tumor entities have better guided our diagnostic strategies and therapeutic arsenal. This chapter aims to give a general overview of the epidemiology, the natural history as well as the pathology of epithelial OC.
Font size:
Interval:
Bookmark:
Similar books «Ovarian Cancer Biomarkers: Mapping to Improve Outcomes»
Look at similar books to Ovarian Cancer Biomarkers: Mapping to Improve Outcomes. We have selected literature similar in name and meaning in the hope of providing readers with more options to find new, interesting, not yet read works.
Discussion, reviews of the book Ovarian Cancer Biomarkers: Mapping to Improve Outcomes and just readers' own opinions. Leave your comments, write what you think about the work, its meaning or the main characters. Specify what exactly you liked and what you didn't like, and why you think so.